Generic placeholder image

Current Immunology Reviews (Discontinued)


ISSN (Print): 1573-3955
ISSN (Online): 1875-631X

The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases

Author(s): Rita Simone and Daniele Saverino

Volume 5, Issue 1, 2009

Page: [54 - 68] Pages: 15

DOI: 10.2174/157339509787314413

Price: $65


CTLA-4, expressed by activated T and B lymphocytes, is a co-stimulatory receptor transducing a potent inhibitory signal. Increasing evidence showed CTLA-4 gene as an important susceptibility locus for autoimmune endocrinopathies and other autoimmune disorders. A soluble form of cytotoxic T lymphocyte-associated antigen-4 (sCTLA-4) was recently found and shown to possess CD80/CD86 binding activity and in vitro immuno-regulatory functions. sCTLA- 4 is generated by alternatively spliced mRNA. Low levels of sCTLA-4 have been detected in normal human serum, but increased serum levels have been observed in several autoimmune diseases (e.g. Graves disease, myasthenia gravis, systemic lupus erythematosus, type 1 diabetes, systemic sclerosis, celiac disease and autoimmune pancreatitis disease). The biological significance of increased sCTLA-4 serum level has not been fully clarified. On one hand, we can hypothesize that sCTLA-4 can specifically inhibit the early T-cell activation by blocking the interaction of CD80/CD86 with the costimulatory receptor CD28. On the other hand, higher levels of sCTLA-4 could compete with membrane-bound CTLA-4 for CD80/CD86, in later T lymphocytes activation phase, causing a reduction of inhibitory signaling. Thus, this doubleedged nature of CD80/CD86 blocking by sCTLA-4 may result in different outcomes during the clinical course of the disease.

Keywords: CTLA-4, immunoregulation, organ specific autoimmunity

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy